IP Verse

Inert Format - EP2943507

The patent EP2943507 was granted to Genmab on Feb 26, 2020. The application was originally filed on Jan 9, 2014 under application number EP14700200A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2943507

GENMAB
Application Number
EP14700200A
Filing Date
Jan 9, 2014
Status
Granted And Under Opposition
Jan 24, 2020
Grant Date
Feb 26, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AMPERSAND PARTNERSCHAFT VON RECHANWALTEN MBBNov 26, 2020SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
AMPERSAND VON RECHTSANWALTENNov 26, 2020SCHIWECK WEINZIERL KOCHADMISSIBLE
MARGARET DIXONNov 25, 2020MEWBURN ELLISWITHDRAWN

Patent Citations (66) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONCN102250246
DESCRIPTIONEP0629240
DESCRIPTIONEP1870459
DESCRIPTIONUS2010015133
DESCRIPTIONUS5057313
DESCRIPTIONUS5545806
DESCRIPTIONUS5545807
DESCRIPTIONUS5569825
DESCRIPTIONUS5589466
DESCRIPTIONUS5625126
DESCRIPTIONUS5633425
DESCRIPTIONUS5661016
DESCRIPTIONUS5733743
DESCRIPTIONUS5770429
DESCRIPTIONUS5789650
DESCRIPTIONUS5814318
DESCRIPTIONUS5874299
DESCRIPTIONUS5877397
DESCRIPTIONUS5973972
DESCRIPTIONUS6077835
DESCRIPTIONUS6331175
DESCRIPTIONUS7262028
DESCRIPTIONUS7612181
DESCRIPTIONUS7951918
DESCRIPTIONUS8236308
DESCRIPTIONWO0046147
DESCRIPTIONWO0070087
DESCRIPTIONWO0109187
DESCRIPTIONWO0114424
DESCRIPTIONWO0243478
DESCRIPTIONWO2007059782
DESCRIPTIONWO2007110205
DESCRIPTIONWO2008003116
DESCRIPTIONWO2008157379
DESCRIPTIONWO2009089004
DESCRIPTIONWO2009097006
DESCRIPTIONWO2010015792
DESCRIPTIONWO2010022692
DESCRIPTIONWO2010080538
DESCRIPTIONWO2010129304
DESCRIPTIONWO2011028952
DESCRIPTIONWO2011069104
DESCRIPTIONWO2011117329
DESCRIPTIONWO2011131746
DESCRIPTIONWO2011143545
DESCRIPTIONWO2011147986
DESCRIPTIONWO2012025525
DESCRIPTIONWO2012025530
DESCRIPTIONWO2012058768
DESCRIPTIONWO2012143524
DESCRIPTIONWO9203918
DESCRIPTIONWO9222645
DESCRIPTIONWO9301227
DESCRIPTIONWO9425585
DESCRIPTIONWO9824884
DESCRIPTIONWO9850431
INTERNATIONAL-SEARCH-REPORTWO2012113813
INTERNATIONAL-SEARCH-REPORTWO2012143524
OPPOSITIONWO2005118635
OPPOSITIONWO2009100309
OPPOSITIONWO2010132872
OPPOSITIONWO2011066389
OPPOSITIONWO2011085343
OPPOSITIONWO2011147982
OPPOSITIONWO2012113813
OPPOSITIONWO2012143524

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- BAUDINO et al., "Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions", J. Immunol., (20080000), vol. 181, pages 6664 - 6669, XP002590016-
OPPOSITION- IDUSOGIE et al., "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc", The Journal of Immunology, (20000000), vol. 164, pages 4178 - 4184, XP002965858-
OPPOSITION- KABAT, E.A.., "Sequences of proteins of immunological interest", Sequences of proteins of immunological interest, (19910000), XP055759504-
OPPOSITION- MORGAN et al., "THE N-TERMINAL END OF THE CH2 DOMAIN OF CHIMERIC HUMAN IGG1 ANTI-HLA-DR IS NECESSARY FOR C1Q, FCGAMMARI AND FCGAMMARIII BINDING", Immunol, (19950000), vol. 86, pages 319 - 324, XP001106372-
OPPOSITION- TAO et al., "STUDIES OF AGLYCOSYLATED CHIMERIC MOUSE-HUMAN IGG", The Journal of Immunology, (19890000), vol. 143, pages 2595 - 2601, XP000984625-
OPPOSITION- CLYNES et al., "Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets", Nat. Medicine, (20000000), vol. 6, no. 4, pages 443 - 446, XP002291039
OPPOSITION- CLYNES et al., "Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets", Nature Medicine, (20000000), vol. 6, no. 4, pages 443 - 446, XP002291039
OPPOSITION- WANG et al., "Monoclonal Antibody Pharmacokinetics and Pharmacodynamics", Clinical Pharmacology & Therapeutics, (20080000), vol. 84, no. 5, pages 548 - 558, XP055152777
OPPOSITION- HESSELL et al., "Fc receptor but not complement binding is important in antibody protection against HIV", Nature, (20070000), vol. 449, pages 101 - 104, XP055077687
OPPOSITION- SHIELDS et al., "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", The Journal of Biological Chemistry, (20010000), vol. 276, pages 6591 - 6604, XP002271092
OPPOSITION- JACOBSEN et al., "Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability", J. Biol. Chem, (20160000), vol. 292, pages 1865 - 1875, XP055604093
OPPOSITION- CANFIELD et al., "THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION", J. Exp. Med., (19910000), vol. 173, pages 1483 - 1491, XP001181027
OPPOSITION- OGANESYAN et al., "Structural characterization of a human Fc fragment engineered for lack of effector functions", Acta Cryst., (20080000), vol. D64, pages 700 - 704, XP002610114
OPPOSITION- OGANESYAN et al., "Structural characterization of a human Fc fragment engineered for lack of effector functions", Acta Cryst, (20080000), vol. D64, pages 700 - 704, XP009108181
OPPOSITION- DATTA-MANNAN et al., "HUMANIZED IGG1 VARIANTS WITH DIFFERENTIAL BINDING PROPERTIES TO THE NEONATAL FC RECEPTOR: RELATIONSHIP TO PHARMACOKINETICS IN MICE AND PRIMATES", Drug Metabolism and Disposition, (20070000), vol. 35, pages 86 - 94, XP009077715
OPPOSITION- LEABMAN et al., "Effects of altered Fc[gamma]R binding on antibody pharmacokinetics in cynomolgus monkeys", mAbs, (20130000), vol. 5, no. 6, pages 896 - 903, XP002770140

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents